Insider Trading Alert - EVTC, CRM And NBY Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 15, 2014, 114 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $538.00 to $2,081,081.25.

Highlighted Stocks Traded by Insiders:

Evertec (EVTC) - FREE Research Report

Harrington Peter, who is President & CEO at Evertec, sold 5,637 shares at $22.35 on Dec. 15, 2014. Following this transaction, the President & CEO owned 64,735 shares meaning that the stake was reduced by 8.01% with the 5,637-share transaction.

The shares most recently traded at $21.54, down $0.81, or 3.76% since the insider transaction. Historical insider transactions for Evertec go as follows:

  • 4-Week # shares sold: 254,972
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 283,272
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 320,272

The average volume for Evertec has been 341,300 shares per day over the past 30 days. Evertec has a market cap of $1.7 billion and is part of the technology sector and computer software & services industry. Shares are down 12.17% year-to-date as of the close of trading on Friday.

EVERTEC, Inc. provides various transaction processing services in Latin America and the Caribbean. The company operates in three segments: Merchant Acquiring, Payment Processing, and Business Solutions. The stock currently has a dividend yield of 1.8%. The company has a P/E ratio of 8.1. Currently, there are 4 analysts who rate Evertec a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EVTC - FREE

TheStreet Quant Ratings rates Evertec as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and generally higher debt management risk. Get the full Evertec Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Salesforce.com (CRM) - FREE Research Report

Benioff Marc, who is Chairman of the Board & CEO at Salesforce.com, sold 37,500 shares at $55.50 on Dec. 15, 2014. Following this transaction, the Chairman of the Board & CEO owned 38.8 million shares meaning that the stake was reduced by 0.1% with the 37,500-share transaction.

Conway Craig, who is Director at Salesforce.com, sold 2,228 shares at $55.72 on Dec. 15, 2014. Following this transaction, the Director owned 10,484 shares meaning that the stake was reduced by 17.53% with the 2,228-share transaction.

The shares most recently traded at $55.41, down $0.31, or 0.57% since the insider transaction. Historical insider transactions for Salesforce.com go as follows:

  • 4-Week # shares sold: 142,569
  • 12-Week # shares sold: 793,569
  • 24-Week # shares sold: 1.7 million

The average volume for Salesforce.com has been 4.7 million shares per day over the past 30 days. Salesforce.com has a market cap of $35.0 billion and is part of the technology sector and computer software & services industry. Shares are down 0.22% year-to-date as of the close of trading on Friday.

salesforce.com, inc. provides enterprise cloud computing solutions to various businesses and industries worldwide. Currently, there are 23 analysts who rate Salesforce.com a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CRM - FREE

TheStreet Quant Ratings rates Salesforce.com as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, growth in earnings per share and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, weak operating cash flow and generally higher debt management risk. Get the full Salesforce.com Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

NovaBay Pharmaceuticals (NBY) - FREE Research Report

Paulson Thomas J, who is Cfo at NovaBay Pharmaceuticals, bought 10,000 shares at $0.68 on Dec. 15, 2014. Following this transaction, the Cfo owned 68,210 shares meaning that the stake was boosted by 17.18% with the 10,000-share transaction.

Najafi Ramin, who is Chief Executive Officer at NovaBay Pharmaceuticals, bought 50,000 shares at $0.65 on Dec. 15, 2014. Following this transaction, the Chief Executive Officer owned 0 shares meaning that the stake was boosted by 100% with the 50,000-share transaction.

The shares most recently traded at $0.66, up $0.01, or 1.52% since the insider transaction. Historical insider transactions for NovaBay Pharmaceuticals go as follows:

  • 4-Week # shares bought: 73,000
  • 4-Week # shares sold: 30,000
  • 12-Week # shares bought: 73,000
  • 12-Week # shares sold: 30,000
  • 24-Week # shares bought: 73,000
  • 24-Week # shares sold: 30,000

The average volume for NovaBay Pharmaceuticals has been 142,100 shares per day over the past 30 days. NovaBay Pharmaceuticals has a market cap of $31.0 million and is part of the health care sector and drugs industry. Shares are down 43.9% year-to-date as of the close of trading on Friday.

NovaBay Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing product candidates for the therapeutic needs of anti-infective market. The company operates in four segments: Dermatology, Ophthalmology, Urology, and Wound Care. Currently, there are no analysts who rate NovaBay Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NBY - FREE

TheStreet Quant Ratings rates NovaBay Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full NovaBay Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

What Do Trade Wars Mean for High Yield Bond Investors?

What Do Trade Wars Mean for High Yield Bond Investors?

Oil Slips From Three-Year Peak After Trump Tweets Anger at OPEC

Oil Slips From Three-Year Peak After Trump Tweets Anger at OPEC

Swiss Franc Slides to Three-Year Low as U.S. Sanctions on Russian Oligarchs Bite

Swiss Franc Slides to Three-Year Low as U.S. Sanctions on Russian Oligarchs Bite

GE Beats Earnings Estimates and 4 Other Stories You Must Know Friday Morning

GE Beats Earnings Estimates and 4 Other Stories You Must Know Friday Morning

General Electric, Honeywell, Wells Fargo and Qualcomm - 5 Things You Must Know

General Electric, Honeywell, Wells Fargo and Qualcomm - 5 Things You Must Know